Work

Supplementary table 1 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma

Year: 2024
Type: supplementary-materials
Abstract: Supplementary table 1: Representativeness of study participants
Language: English
Subfield: Ophthalmology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4398167352
Cites:
Cited by:
Related to: 10